Prenatal drug exposure: infant and toddler outcomes

Emmalee S Bandstra1, Connie E Morrow, Elana Mansoor

  • 1University of Miami Miller School of Medicine, Department of Pediatrics, Division of Neonatal Medicine, Miami, FL 33101, USA. ebandstr@med.miami.edu

Insights

Maternal opioid and cocaine use during pregnancy can impact infant development. While opioids may cause neonatal abstinence syndrome, cocaine exposure is linked to subtle neurodevelopmental deficits, with long-term effects still under investigation.

Area of Science:

  • Obstetrics and Gynecology
  • Pediatrics
  • Neonatology
  • Developmental Psychology

Background:

  • Maternal drug use during pregnancy, particularly opioids and cocaine, presents significant risks to infant and toddler development.
  • Opioid use includes heroin and treatments like methadone and buprenorphine, while cocaine use encompasses crack cocaine.
  • Previous research on prenatal cocaine exposure led to concerns about severe developmental issues, often termed 'crack baby' syndrome.

Purpose of the Study:

  • To review the scientific literature on the effects of maternal opioid and cocaine use on infant and toddler outcomes from birth to age three.
  • To highlight findings from controlled studies comparing different opioid treatments and cocaine exposure effects.
  • To discuss the diagnosis and management of neonatal abstinence syndrome.

Main Methods:

  • Systematic review of current scientific literature.
  • Analysis of prospective studies comparing drug-exposed and non-exposed infants and toddlers.
  • Focus on outcomes including anthropometric growth, neurobehavior, sensory function, and cognitive, motor, and language development.

Main Results:

  • Opioid exposure, including methadone and buprenorphine, can lead to neonatal abstinence syndrome and neurobehavioral deficits.
  • Prenatal cocaine exposure is associated with statistically significant but subtle decrements in neurobehavioral, cognitive, and language function.
  • The impact of cocaine exposure may be moderated by other exposures and the caregiving environment, with less severe outcomes than initially feared.

Conclusions:

  • Prenatal opioid exposure requires careful management of neonatal abstinence syndrome and monitoring for neurobehavioral deficits.
  • Prenatal cocaine exposure may result in subtle developmental differences, necessitating further longitudinal research to understand long-term impacts.
  • The caregiving environment plays a crucial role in mediating developmental outcomes for infants exposed to drugs in utero.

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...